Clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults
Abstract
Objective To evaluate the clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults.Methods 86 cases with determined diagnosis of community acquired pneumonia(mycoplasma pneumonia)of respiratory department in our hospital were chosen,in which,28 patients treated with moxifloxacin(moxifloxacin group)and 22 patients treated with cefuroxime combined with azithromycin(control group)were included in the analysis.The clinical efficacy of the 2 groups was assessed.Results No failure case was observed in both groups.Compared with control group,the moxiflocaxin group had higher defervescence rate(75.0% vs.45.5%),shorter defervescence time(3.07 d vs.5.23 d).The time from the treatment to the clinical stability(2.54 d vs.4.10 d,P0.05)and the intravenous antibiotic treatment course(8.61 d vs.11.41 d,P0.05)in moxiflocaxin group were shorter than those in control group.There was no significant difference in the total course of antibiotics use and the hospitalization time between the 2 groups.Conclusion The clinical efficacy of the 2 groups was similar,and the moxifloxacin group has shorter defervescence time,higher 72 h defervescence rate,shorter clinical stability time and shorter intravenous antibiotic course.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.